Why You Can Lose Muscle on GLP-1 Medications

• GLP-1-based medications can produce substantial weight loss. Most of that loss comes from fat, but some can also come from lean mass, including muscle.
• In a body-composition substudy of semaglutide, lean body mass decreased by 9.7%. In a tirzepatide substudy, approximately 25% of total weight lost was lean mass.
• Preserving muscle matters during significant weight loss, which is why adequate protein and resistance training are increasingly emphasized alongside GLP-1 treatment.
• Another challenge can emerge when treatment is reduced or stopped: the appetite-suppressing effect fades, and hunger, cravings and the urge to snack can become harder to manage again.
• Weight regain after stopping GLP-1-based treatment is common. In the STEP 1 extension, participants regained roughly two-thirds of their prior semaglutide-associated weight loss within one year.
• Carb Fence works through a completely different mechanism. Its patented SiPore® technology works locally in the gut, slowing the breakdown of carbohydrates and fats rather than acting systemically.
• Carb Fence has evidence supporting appetite control, fullness, reduced cravings and less urge to snack, as well as reductions in fat mass while preserving lean body mass. 

GLP-1 medications have changed weight management. 

For many people, medications such as semaglutide and tirzepatide can produce substantial results. Hunger becomes quieter. Portions become smaller. Cravings may become easier to manage. And weight that may have been difficult to lose through lifestyle changes alone can finally begin to move. 

That is real progress. 

But the number on the scale does not tell you what kind of weight you lost. 

And there is another question that often becomes important later: 

What happens when the medication is reduced or stopped? 

Those two questions — preserving muscle while losing weight, and managing appetite when pharmacological appetite suppression decreases — are becoming increasingly important parts of the GLP-1 conversation. 

When you lose a meaningful amount of body weight, the body rarely loses fat alone. 

Some lean tissue can be lost too. 

Researchers usually measure this as lean body mass, which includes skeletal muscle but also water, organs and other non-fat tissue. So a reduction in lean mass should not automatically be interpreted as the same amount of muscle loss. 

Still, muscle preservation matters. 

And body-composition studies of GLP-1-based medications show why it deserves attention. 

In an exploratory body-composition analysis of the STEP 1 study, participants receiving semaglutide lost substantial body weight. 

The majority of the change was favorable: total fat mass fell by 19.3% and visceral fat mass by 27.4%. 

But total lean body mass also decreased by 9.7%. 

That does not mean semaglutide causes disproportionate muscle wasting. In fact, because fat mass fell faster than lean mass, lean tissue represented a greater proportion of total body weight after treatment. 

But it does show something the scale cannot: 

Significant weight loss can include significant loss of lean tissue as well as fat. 

A body-composition substudy of the SURMOUNT-1 trial found a similar pattern with tirzepatide. 

After 72 weeks, body weight decreased by 21.3%, fat mass by 33.9%, and lean mass by 10.9%. 

Approximately 75% of the weight lost was fat mass and 25% was lean mass. 

Again, most of the weight lost was fat. 

That is important. 

But if someone loses 20 kilograms, even a minority of that weight coming from lean tissue can represent a meaningful change. 

The goal therefore should not simply be: 

Lose as much weight as possible. 

A better goal is: 

Lose fat while preserving as much muscle as possible. 

GLP-1-based medications are effective partly because they can dramatically change appetite and food intake. 

Controlled studies of semaglutide show reductions in hunger, cravings and ad-libitum calorie intake. In one randomized trial of semaglutide 2.4 mg, participants consumed substantially less food and reported greater appetite suppression and better control of eating compared with placebo. 

That is a major reason the medications work. 

But when someone begins eating substantially less, the body still needs energy and nutrients. 

If total intake falls significantly, maintaining enough protein can become more difficult. And without a reason to preserve muscle — particularly resistance exercise — some lean tissue can be lost alongside fat. 

This is not unique to GLP-1 treatment. Lean mass loss can occur during substantial weight loss through many different approaches. 

But the amount of weight GLP-1-based medications can produce means that muscle preservation deserves deliberate attention rather than being an afterthought. 

Protein provides the amino acids the body needs to maintain and repair muscle tissue. 

When appetite is substantially reduced, protein becomes something worth planning for rather than assuming will happen naturally. 

Protein-rich foods may need to take priority within smaller meals. 

Resistance training sends a powerful signal that muscle tissue is still needed. 

You do not need to become a bodybuilder. 

Regular strength-based exercise — weights, machines, resistance bands or body-weight movements — can help make preserving muscle part of the weight-loss strategy rather than something considered afterwards. 

For many people, there is another challenge. 

It comes later. 

While the medication is working, appetite may feel fundamentally different. 

You think about food less. 

You become full sooner. 

The urge to snack may diminish. 

Cravings that previously felt difficult to ignore may become much quieter. 

That can make eating less feel surprisingly manageable. 

Then the dose comes down. Or treatment stops. 

And the environment has not changed. 

The same food is still around. The same habits still exist. The same restaurants, snacks, workdays and evenings on the sofa are still there. 

But the pharmacological effect that had been helping to control appetite is no longer the same. 

For some people, hunger becomes more noticeable again. 

Snacking becomes more tempting. 

Sweet cravings become harder to ignore. 

Food starts taking up more mental space. 

And maintaining the eating pattern that felt relatively effortless on treatment can suddenly require much more conscious effort. 

This is not simply anecdotal. 

Weight regain after discontinuing GLP-1-based weight-loss therapy has been clearly documented in randomized clinical research. 

In the STEP 1 extension, participants who had received semaglutide lost an average of 17.3% of their body weight during treatment. 

One year after semaglutide was withdrawn, they had regained approximately two-thirds of that previous weight loss. 

Tirzepatide studies show the same broad challenge. In the randomized SURMOUNT-4 trial, participants who stopped tirzepatide and switched to placebo experienced substantial weight regain, while those who continued treatment maintained and extended their weight reduction. 

This does not mean that everyone who stops treatment will regain all the weight they lost. 

And it does not mean that muscle loss is the reason weight returns. 

Weight regulation is much more complex than that. 

But it does demonstrate something important: 

Coming off a GLP-1 can be a meaningful transition, not simply the end of treatment. 

The challenge after GLP-1 treatment is not necessarily knowing what healthy food looks like. 

Most people already know that. 

The difficult part can be doing the same things when hunger, cravings and food noise are louder again. 

This is where maintaining results becomes very practical. 

Can you feel satisfied after a normal meal? 

Can you make it to the next meal without constantly thinking about snacks? 

Can you eat carbohydrates without experiencing the same pull toward something sweet afterwards? 

Can you maintain the habits that helped you lose weight when appetite is no longer being controlled to the same degree pharmacologically? 

These are everyday questions. 

And they are exactly where a meal-level approach becomes interesting. 

Carb Fence does not try to reproduce the pharmacology of a GLP-1 medication. 

It works differently. 

Carb Fence is powered by patented SiPore® technology, which works locally in the gut and does not enter the bloodstream. 

Its precisely engineered pores temporarily entrap a portion of digestive enzymes involved in breaking down carbohydrates and fats. 

This slows digestion, creating a more gradual post-meal response. 

There is no loading period. 

SiPore® starts working with the first meal you take it with. 

That makes it a fundamentally different approach to weight management: instead of relying on systemic hormone signaling, it works at the level of the meal itself. 

Carb Fence has not been clinically studied as a treatment for GLP-1 withdrawal or as a way to prevent post-GLP-1 weight regain. 

But the challenges Carb Fence has been shown to address overlap closely with several of the practical challenges people may face as pharmacological appetite suppression decreases. 

In a real-world evidence study of 69 people using Carb Fence: 

• Hunger decreased by 19% 

• Urge to snack decreased by 30% 

• Sugar cravings decreased by 25% 

• Post-meal fatigue decreased by 24% 

Carb Fence supports appetite control, promotes satiety and fullness, and helps reduce sugar cravings. 

That matters because maintaining weight is rarely about one dramatic decision. 

It is about what happens between meals. 

The snack you did or did not need. 

The craving that passed. 

The dinner that actually left you satisfied. 

The ability to repeat those patterns tomorrow. 

If preserving muscle is one of the priorities during a weight-loss journey, the body-composition research behind Carb Fence is particularly relevant. 

Backed by preclinical research, confirmed in a major randomized, placebo-controlled clinical trial and further supported by real-world evidence, Carb Fence reduces fat mass while preserving lean body mass, supporting healthy body composition. 

In the 12-week SHINE trial, 318 adults with prediabetes or early type 2 diabetes participated in a randomized, double-blind, placebo-controlled evaluation of SiPore®. 

The research showed reductions in body weight and fat mass while lean mass was preserved. 

Measures of abdominal body composition also improved. 

That is an important distinction. 

Because a lower number on the scale is not the only goal. 

What you preserve matters too. 

GLP-1-based medications can be highly effective tools for weight management. 

For people who use them, the goal should not be to diminish what they can achieve. 

It should be to think beyond the initial weight loss. 

How do you protect muscle while losing weight? 

How do you build habits that remain useful if treatment changes? 

How will you manage meals when appetite feels different again? 

How do you support the body composition you actually want — less excess fat, with lean mass preserved? 

For many people, the answer will involve several pieces working together: 

Protein. Strength training. Regular movement. Meal structure. And strategies that make appetite, cravings and everyday eating easier to manage. 

Carb Fence offers one additional tool. 

Its SiPore® technology works locally in the gut from the first meal, helping reduce the impact of carbohydrates and fats during digestion. 

It supports appetite control, fullness and fewer cravings and urges to snack. 

And the evidence shows something particularly relevant for anyone thinking beyond the scale: 

Fat mass down. Lean mass preserved. 

Explore Carb Fence

Less impact per meal. Stability over time.

-----

1. Wilding JPH, Batterham RL, Calanna S, et al. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study. Journal of the Endocrine Society. 2021;5(Suppl 1):A16–A17. doi:10.1210/jendso/bvab048.030. 

2. Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism. 2025;27(5):2720–2729. doi:10.1111/dom.16275. 

3. Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021;23(3):754–762. 

4. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022;24(8):1553–1564. doi:10.1111/dom.14725. 

5. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38–48. doi:10.1001/jama.2023.24945. 

6. Baek J, et al. Effect of Engineered Mesoporous Silica Particles with Tailored Pore Size on Glycaemic Control in Individuals with Prediabetes or Type 2 Diabetes: A Randomised, Double-Blind, Placebo-Controlled SHINE Trial. eClinicalMedicine. 2026;97:104042. 

7. Sigrid Therapeutics. U.S. Real-World Evidence Study. 2025. N=80 overall; appetite outcomes N=69.